Bioquimica Da Dor
Bioquimica Da Dor
comigo!
https://doi.org/10.1007/978-3-030-12281-2
CHRONIC PAIN
https://doi.org/10.1007/978-3-030-12281-2
Basic Science of Pain
DOI 10.1007/978-3-662-46450-2
ESSENTIALS OF Pain Medicine
ISBN 9780323401968
Academic Pain Medicine
https://doi.org/10.1007/978-3-030-18005-8
Basic Science of Pain
ISBN 9780323401968
Food, pain, and drugs: Does it matter what pain patients eat?
https://doi.org/10.1007/978-3-030-12281-2
Pain: Pathways and Physiology
Current medical research and opinion 2018, VOL. 34, NO. 7, 1169–1178
Pattern recognition receptors in chronic pain: mechanisms and therapeutic implications
Regulation of pain induction via macrophage-nociceptor interactions. (a) In macrophages, activation of TLRs (e.g. TLR4 and TLR9) by PAMPs and DAMPs
increases the synthesis and release of inflammatory cytokines and chemokines (e.g. TNF, IL-1b, CCL2, CXCL1) and lipid mediators (e.g. PGE2) via MyD88
and NF -kB. PAMP and DAMP can be induced by bacteria infection, tissues injury, or chemotherapy (e.g. paclitaxel). These inflammatory mediators act
on their respective receptors (e. mediators to pain (Figure 3), as well as itch, a distinct sensation that triggers scratching [9,10]. After sensing these
noxious stimuli, action potentials initiated at the peripheral terminals of nociceptors are carried forward to 2nd order nociceptive neurons in the dorsal
horn of the spinal cord or brain stem via their central projections.
Current medical research and opinion 2018, VOL. 34, NO. 7, 1169–1178
Chronic Pain: Pathophysiology and Mechanisms
https://doi.org/10.1007/978-3-319-64922-1
Mechanisms of microbial–neuronal interactions in pain and nociception
Figure 2. Peripheral mechanisms of trigeminal neuropathic pain. Peripheral nerve injury releases inflammatory mediators including prostaglandin E2 (PGE2),
cytokines and neuropeptides including brain-derived neurotrophic factor (BDNF), which sensitizes peripheral nerve terminals by depolarizing nociceptors.
Expression of peripheral receptors including the transient receptor potential vanilloid 1 (TRPV1) and transient receptor potential cation channel, subfamily
A, member 1 (TRPA1). Changes in ion channel expression and activity on trigeminal neurons increases excitability as do activated satellite glial cells (SCG),
which increase in number. Excitability of the TG neurons leads to increased release of neuropeptides substance P (SP) and calcitonin gene-related peptide
(CGRP) to postsynaptic regions in the trigeminal spinal caudalis (brain stem).
Medicines 2019, 6, 91
TRP Channel Cooperation for Nociception: Therapeutic Opportunities
https://doi.org/10.1007/978-981-15-2933-7
Pain Care Essentials and Innovations
ISBN: 978-0-323-72216-2
Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment
Figure 2
Opioid modulation of signaling and synaptic transmission. (a) Presynaptic and postsynaptic effects of opioids on nociception. (Left)Noxious stimuli trigger action potential firing along DRG nociceptors. Upon reaching the
synaptic terminal, VGCCs ( yellow) open, facilitating neurotransmitter release. These neurotransmitters (e.g., glutamate) then open postsynaptic AMPA and NMDA receptors, which continue the nociceptive signals
along pain circuits. (Right) Activation of opioid receptors promotes dissociation of inhibitory Gα and Gβγ protein subunits. Gα subunits suppress adenylate cyclase, and Gβγ subunits presynaptically inhibit VGCC opening
and postsynaptically activate GIRK channels, resulting in reduced neurotransmitter release and membrane hyperpolarization, respectively. (b) Biased signaling pathways. Agonist binding to opioid receptors causes
conformational changes that promote distinct recruitment of G protein and arrestin effector signaling cascades. While G proteins mediate the inhibitory action of opioid signaling on neurotransmission, arrestin
signaling is required both for internalization of opioid receptors and for kinase activities. The balance between G protein and arrestin signaling is thought, in part, to determine the analgesic versus detrimental effects of
opioids. (c) Within pain circuits opioid receptors are activated by opioid analgesics such as enkephalin (endogenous) or morphine (exogenous). Endogenous opioids, such as enkephalins, can be released from infiltrating
immune cells at the site of injuries and from neurons in the central nervous system. Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; DRG, dorsal root ganglion; EPSC, excitatory
postsynaptic current; ERK, extracellular signal regulated kinase; GIRK, G protein inwardly rectifying potassium; JNK, c-Jun
N-terminal kinase; NMDA, N-methyl-D-aspartate; RVM, rostral ventromedial medulla; VGCC, voltage-gated calcium channel.
Figure 2
Opioid modulation of signaling and synaptic transmission. (a) Presynaptic and postsynaptic effects of opioids on nociception. (Left)Noxious stimuli trigger action potential firing along DRG nociceptors. Upon reaching the
synaptic terminal, VGCCs ( yellow) open, facilitating neurotransmitter release. These neurotransmitters (e.g., glutamate) then open postsynaptic AMPA and NMDA receptors, which continue the nociceptive signals
along pain circuits. (Right) Activation of opioid receptors promotes dissociation of inhibitory Gα and Gβγ protein subunits. Gα subunits suppress adenylate cyclase, and Gβγ subunits presynaptically inhibit VGCC opening
and postsynaptically activate GIRK channels, resulting in reduced neurotransmitter release and membrane hyperpolarization, respectively. (b) Biased signaling pathways. Agonist binding to opioid receptors causes
conformational changes that promote distinct recruitment of G protein and arrestin effector signaling cascades. While G proteins mediate the inhibitory action of opioid signaling on neurotransmission, arrestin
signaling is required both for internalization of opioid receptors and for kinase activities. The balance between G protein and arrestin signaling is thought, in part, to determine the analgesic versus detrimental effects of
opioids. (c) Within pain circuits opioid receptors are activated by opioid analgesics such as enkephalin (endogenous) or morphine (exogenous). Endogenous opioids, such as enkephalins, can be released from infiltrating
immune cells at the site of injuries and from neurons in the central nervous system. Abbreviations: AMPA, α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid; DRG, dorsal root ganglion; EPSC, excitatory
postsynaptic current; ERK, extracellular signal regulated kinase; GIRK, G protein inwardly rectifying potassium; JNK, c-Jun N-terminal kinase; NMDA, N-methyl-D-aspartate; RVM, rostral ventromedial medulla; VGCC,
voltage-gated calcium channel.
https://doi.org/10.1007/978-981-13-1756-9
Advances in Experimental Medicine and Biology
https://doi.org/10.1007/978-981-13-1756-9
Advances in Experimental Medicine and Biology
https://doi.org/10.1007/978-981-13-1756-9
Basic pharmacology of local anaesthetics
Advances in Pharmacology
Modulation of Chronic Pain by Metabotropic Glutamate Receptors
Advances in Pharmacology
Pharmacotherapy for Neuropathic Pain: A Review
ole of TRP channels in skin homeostasis and skin diseases. The skin-expressed TRP channels can
either contribute to maintaining normal skin physiology or play important roles in the
pathogenesis of skin diseases.
https://www.ncbi.nlm.nih.gov/books/NBK476120
Novel Agents in Neuropathic Pain, the Role of Capsaicin: Pharmacology, Efficacy, Side Effects, Different Preparations
Figure 8.1
Transduction of pain signal. (a) Nociceptor stimulation by tissue damage. Nociceptive signals and proinflammatory compounds trigger an action
potential along the nociceptive fiber toward the central nervous system to be perceived as pain. (b) Nociceptive signals are detected by some
members of the TRP family of ion channels, which are directly activated by their agonists and indirectly by proinflammatory mediators. (DRG, dorsal
root ganglion; TG, trigeminal ganglion.)
https://www.ncbi.nlm.nih.gov/books/NBK476120
Treatment of chronic neuropathic pain: purine receptor modulation
Br J Pharmacol. 2020;177:580–599
Histamine, histamine receptors, and neuropathic pain relief
Br J Pharmacol. 2020;177:580–599
Cannabinoids in the descending pain modulatory circuit: Role in inflammation
Figure 3: Schematic illustration of functional and metabolic changes (peptides, proteins, and mRNA) of the brain-gut axis by acupuncture in visceral pain studies. In human, acupuncture
consistently enhanced the functional activity in the thalamus and insula, the core brain regions of pain processing. In animal, a great variety of metabolic changes have been reported as
well as functional neural activities, demonstrating that acupuncture induces awide range of changes through the brain-gut axis in visceral pain.ACC: anterior cingulate cortex;AMG:
amygdala; CC: central canal; DH: dorsal horn; DRG: dorsal root ganglion; DRN: dorsal raphe nucleus; HyTH: hypothalamus; INS: insula; MED: medulla; NR2B: N-methyl-D-aspartate receptor
subunit; PAG: periaqueductal gray; PFC: prefrontal cortex; P2X3: P2X purinoceptor 3; SC: somatosensory cortex; sub P: substance P; TH: thalamus; 4th V: fourth ventricle.